A new technology could transform how children are diagnosed and treated for sleep disorders.
Glasgow-based medtech company Seluna has launched a major clinical study in partnership with the Royal Hospital for Children in Glasgow to validate its diagnostic software.
The clinical study involves 500 anonymised patients under 18 and will run until the end of 2025. It aims to verify Seluna's software as a medical device (SaMD).
It is part of a wider, multi-site validation programme, with additional NHS sites expected to join by the end of the year.
Seluna recently secured nearly £650,000 in funding from investors including Gabriel Investment Syndicate, Scottish Enterprise, the University of Strathclyde and STAC Invest.
Dr Scott Black, co-founder and chief executive of Seluna, said: "Paediatric sleep diagnostics has been underserved for too long.
"It’s a complex challenge, which is why existing tools weren’t built for children – until now.
"This validation study will demonstrate clinical impact and make a clear statement: we’re here to set a new standard.
"We’re here to innovate, drive change and compete internationally, with backing from investors who recognise the potential of the paediatric healthcare market."
Dr Yola Jones (L) and Dr Scott Black (R), co-founders of Seluna (Image: Supplied)
Read more: World-leading laser centre to expand operations in Glasgow
Currently, sleep studies are manually reviewed, a labour-intensive process that can create delays in diagnosis.
Seluna's software is designed to support clinicians in diagnosing and managing paediatric sleep apnoea.
It automatically interprets sleep studies using a suite of machine learning algorithms.
Dr Ruth Hamilton, consultant clinical scientist at the Royal Hospital for Sick Children and principal investigator for the study, said: "What makes Seluna’s approach so compelling is its focus on explainable AI.
"As clinicians, we need to understand why the technology is making certain recommendations.
"Seluna’s focus on interpretability builds the trust we need to confidently use this technology in clinical practice.
"It will help take pressure off busy departments and allow us to stop firefighting wait lists."
Dr Ruth Hamilton, Consultant Clinical Scientist at Royal Hospital for Sick Children, Glasgow, and principal investigator for the study (Image: Supplied) The company aims to achieve Class I medical device classification in the UK by the end of 2026, paving the way for adoption across the NHS and private healthcare.
It also plans to seek Class II FDA approval in the United States by the end of 2027.
Seluna believes its technology could identify which children will benefit most from specific therapies, potentially reducing unnecessary surgeries and ensuring those in need receive timely care.
Dr. Haytham Kubba, Pediatric ENT Surgeon at Royal Hospital for Children, Glasgow, and principal investigator (Image: Supplied)
Read more: HMRC and the parents trying to beat the childcare 'cliff edge' that loses £30k
Dr Haytham Kubba, paediatric ear, nose and throat surgeon at the Royal Hospital for Children and chief investigator on the study, said: "Adenotonsillectomy for sleep apnoea is the most common paediatric surgery for the most common reason but right now, we simply don’t know if we’re operating on the right children.
"Seluna is developing a solution which could dramatically improve our ability to identify and prioritise the children who need help most urgently.
"It has the potential to transform how we approach paediatric sleep medicine."
Share